ExamPat

Kevin S Orwig

USPTO Patent Examiner·Active 2019 to 2026

Kevin S Orwig is a USPTO patent examiner who has handled 14 ex parte reexaminations between 2019 and 2026, with 7 currently open. These reexams concentrate in Chemistry & Materials, Life Sciences & Consumer, and Mechanical & Manufacturing. ExamPat indexes the full prosecution record for each of these cases, including office-action grounds, certificate outcomes, and downstream PTAB and federal-circuit decisions.

Filings by year

2
19
1
22
1
23
4
24
4
25
2
26

Technology mix

Chemistry & Materials7 (50%)
Life Sciences & Consumer5 (36%)
Mechanical & Manufacturing2 (14%)

Compare against all examiners

Eight side-by-side metrics: case volume, pendency, OAs per reexam, rejection mix, SNQ denial rate, certification rate, and PTAB appeal rate, with a Δ column showing where this examiner runs higher or lower than the corpus.

  • Average and median pendency, both for this examiner and the corpus
  • Rejection basis split (102 / 103 / 112) head-to-head
  • Certification, SNQ denial, and PTAB appeal rates

Certificate outcome distribution

How this examiner's certificates split across the six possible outcomes: all claims confirmed, confirmed with amendment, confirmed with new claims, mixed, or all claims canceled. Includes share comparison to the corpus distribution.

  • Count and share for each of the six outcome buckets
  • Δ vs. corpus distribution in percentage points
  • Useful for setting realistic patent-owner expectations

Event-to-event timing

Median time for this examiner's cases at each prosecution stage — filing to first office action, filing to NIRC, and filing to certificate — with corpus comparison and sample size.

  • Median in months per transition
  • Side-by-side with the corpus median
  • n column showing how many of this examiner's cases completed each transition

Recent reexaminations (14)

Control #FiledPatentTitlePendencyStatus
90/016,154Apr 3, 202612,151,003Stable, concentrated radionuclide complex solutions—Open
90/016,039Mar 11, 202612,168,063Stable, concentrated radionuclide complex solutions—Open
90/015,784Dec 15, 202512,151,863PUSH THROUGH BLISTER PACKAGE WITH PLASTIC LIDDING—Open
90/015,652Oct 30, 202512,151,863PUSH THROUGH BLISTER PACKAGE WITH PLASTIC LIDDING—Open
90/015,636Oct 24, 202511,203,748PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN—Open
90/019,884Mar 18, 20258,114,426GRANULAR TURF SAFE MESOTRIONE COMPOSITIONS11 moClosed
90/019,692Oct 3, 202411,033,495MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES10 moClosed
90/019,548Jun 25, 202410,865,441Mutant Taq Polymerase for Faster Amplification13 moClosed
90/019,516May 21, 202410,392,438BISPECIFIC ANTIBODIES—Open
90/019,502May 2, 202411,365,394ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF17 moClosed
90/019,310Nov 29, 20239,596,871Canola Germplasm Exhibiting Seed Compositional Attributes That Deliver Enhanced Canola Meal Nutritional Value—Open
90/015,080Jul 26, 20227,064,197SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS40 moClosed
90/014,270Feb 26, 20197,064,197System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids81 moClosed
90/014,272Feb 26, 20197,064,197SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS81 moClosed

Other USPTO reexam examiners

Get the full reexam analytics

Compare Kevin S Orwig against the full corpus, see the certificate-outcome split, drill into event timing, filter the case list, and export. Free to sign up.